Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Investigated for use/treatment in prostate cancer, psoriasis and hyperparathyroidism.
- Mechanism
- Curator reviewed
Inecalcitol is an analogue of calcitriol, the naturally active metabolite of vitamin D. Calcitriol and their analogues activate the vitamin D receptor (VDR). Vitamin D has a major role in regulating calcium absorption from the gut, storage in mineral form in the bones, and excretion by the kidney and effectively prevents rickets in infants. Vitamin D and calcitriol can cause hypercalcemia at high or frequently repeated doses; in turn, hypercalcemia can cause kidney toxicity by accumulation of calcium-containing micro-crystals and heart and muscle dysfunction by impairing contractions. [Hybrigenics Website] The mechanism of action is currently unknown, but it is proposed that inecalcitol exerts its superagonistic action through enhancing coactivator binding by the VDR.
- Primary indication
- Investigated for use/treatment in prostate cancer, psoriasis and hyperparathyroidism.Curator reviewed
- Formula / weight
- C26H40O3 · 400.603 g/mol (avg)
- Code names
- TX-522
Resolves to
HHGRMHMXKPQNGF-WNSNRMDMSA-NSMILES[H][C@@]1(CC[C@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)CC#CC(C)(C)OWhat you can answer from here — as of August 26, 2024
Which drugs share a target with Inecalcitol, and which of those have an active Phase 3 trial?